tbuckley/cabot-search huggingface dataset:
Growth and Hormonal Responsiveness of Human Endometrial Carcinoma After Heterologous Transplantation to Neonatal Rats<xref ref-type="fn" rid="FN2">2</xref>
Authors: John-Gunnar Forsberg, M.D., Staffan Nordqvist, M.D.
Journal: JNCI Journal of the National Cancer Institute (1969)

Pieces of human endometrial adenocarcinoma, obtained by curettage from previously untreated women, were grafted into the thigh musculature of newborn Sprague-Dawley rats. The young rats were given intraperitoneal injections of an antilymphocyte immune globulin and subcutaneous injections of progesterone and 17β-estradiol. They were killed 14 days after the transplantation. Pieces from 19 endometrial adenocarcinomas were grafted; 4 carcinomas were omitted for different reasons but the remaining 15 are accounted for. Most of the grafts showed an excellent or good survival. Hormonal effects were seen in 5 of 8 grade I carcinomas (well differentiated) and in 3 of 7 grade II carcinomas (poorly differentiated or various degrees of differentiation).
Effect on in vivo immunogenicity of human idiotype-KLH vaccines by maleimide conjugation
Authors: K. Kafi, D. Betting, R. Yamada, K. Steward, J. M. Timmerman
Journal: Journal of Clinical Oncology (2008)

8576 Tumor-specific immunoglobulin (idiotype, Id) can serve as a target for therapeutic vaccination against B cell malignancies. Id chemically-coupled to the immunogenic foreign carrier protein keyhole limpet hemocyanin (Id-KLH) has shown promising results in phase I/II clinical trials, and phase III trials are underway. However, many immunized patients fail to mount anti-Id immune responses, and one phase III trial recently failed in its primary efficacy endpoint. Id is traditionally coupled to KLH using glutaraldehyde (glut), which crosslinks via lysine, cysteine, tyrosine and histidine residues. We recently developed an alternative Id-KLH conjugation method employing maleimide (mal) chemistry, and found markedly improved anti-tumor efficacy in several murine lymphoma models owing to increased induction of tumor- specific CD8+ T cells and antibodies. To move towards clinical application, we conjugated human monoclonal Igs (IgG1 or IgG3) to KLH using mal or glut and tested their immunogenicity in vivo. The immunoreactivity of polyclonal anti-human IgG sera towards various conjugates was measured by ELISA. Surprisingly, glut conjugates of IgG1 and IgG3 showed only 1–16.5% of the reactivity of free IgG, while that of mal conjugates was highly preserved (91.7–99.7%), indicating a substantial reduction in antigenic content after glut conjugation. Mice were vaccinated with various conjugates plus GM-CSF and sera tested for binding to each immunogen. In all four cases, mal Ig-KLH resulted in higher (2.1 to 14.2-fold) anti-Id antibody titers than glut Ig-KLH (Table below). Analysis of T cell responses to human Ig-KLH vaccines is ongoing. In conclusion, like murine lymphoma Id proteins, human mal Ig-KLH conjugates are more immunogenic than glut conjugates. The observed destruction of human IgG antibody epitopes by glut may help explain the unfavorable results seen in some patients immunized with glut Id-KLH. We conclude that maleimide Id-KLH therapeutic vaccines deserve testing in human lymphoma trials. Anti-Id antibody levels in vaccinated mice (mcg/ml) IgG1 (Rituximab) IgG1 (Trastuzumab) IgG3 (Kappa) IgG3 (Lambda) Maleimide Id-KLK 136 1950 454 420 Glutaraldehyde Id-KLH 40 137 214 140 No significant financial relationships to disclose.
Computed tomography in screening for smoking induced emphysema
Authors: Martin Anderson, Gunnar Engström, Lars Nordenmark, Dag Mohlkert, Elmira Rouzbeh, Maria Gerhardsson de Verdier, Ulf Nihlén, Thomas Fehniger, Magnus Dahlbäck, Magnus Svartengren
Journal: European Respiratory Journal (2013)

Computerized methods and visual assessment of computed tomography (CT) scans were compared in a subsample of a population based twin study to explore the relationships between emphysema, smoking, decreased pulmonary function, and elastin degradation products.

138 twins were investigated. Two radiologists classified the CT-scans by presence of Centrilobular Emphysema (CE). PD15 (i.e. the cut off value in Hounsfield units [HU] for the 15% darkest areas) as well as fixed HU limits were used in the computerized analyses. Lung function and urinary desmosines were measured by specialist laboratories.

There was no significant relationship between PD15 and current smoking or pack-years. Low C-reactive protein and body-mass-index were associated with low PD15 (p<0.01 for both). Also sex was significantly associated with PD15. Of the lung function measures, FEV1/FVC (low values) and FVC (high values) were associated with low PD15. Associations between these measures and CT findings were strongest for the upper third of the lung.

106 of the 138 twins had CE, 27 had not CE. Five subjects were omitted due to poor quality and technical problems. In the CE group FEV1 % pred. was lower (p=0.018), as was the FEV1/FVC-ratio and DLCO (both p<0.001), further, CRP was higher (p= 0.014) and U-desmosines showed a tendency to be higher (p= 0.054).The proportion with CE was associated with PD15.

In this population based study on mild COPD, the lung function and biomarker parameters of disease were closer associated to visual scoring of emphysema than to quantitative CT measurements. If quantitative measures should be used for staging and phenotyping smoking induced emphysema, such measurements should be focused on the upper third of the lungs.
Possible Role of Interleukin-10 (IL-10) and CD40 Ligand Expression in the Pathogenesis of Hypergammaglobulinemia in Human Immunodeficiency Virus Infection: Modulation of IL-10 and Ig Production After Intravenous Ig Infusion
Authors: Fredrik Müller, Pål Aukrust, Ingvild Nordøy, Stig S. Frøland
Journal: Blood (1998)
History of mesothelioma
Authors: M Greenberg
Journal: European Respiratory Journal (1997)

MCDONALD and MCDONALD [1] present a version of the history of mesothelioma that for the sake of scholarship requires amendment.The references to the growth of knowledge of an association between mesothelioma and asbestos exposure are at variance with plain reading of the publications they cited.For example, GLOYNE [2] stated that he considered it worthwhile recording his two cases of squamous carcinoma of the lung occurring in asbestosis, "...not in any attempt to make out a case for an aetiological association of these two diseases, but in order to emphasize certain histological points in which one disease appears to bear upon the other".In each case the malignant lesion was very small, appeared to rise in the wall of a small bronchus and was not recognized in life.Nowhere is the question of mesothelioma referred to.The authors interpret CARTIER [3] as giving his opinion that "...two such rare cancers in a small series of only eight cases suggested an occupational origin...".It is easy to misunderstand this, as the text is unclear.CARTIER [3] was concerned to discount asbestos as a cause of bronchogenic carcinoma, and not to make a case for mesothelioma being occupationally determined.The conference rapporteur reported him as saying: "...it seems obvious that many points would need discussion before anyone will be able to establish a causal relationship between these pathological findings and the asbestos factor.Is it not more logical to think that the same causal factor will produce the same type of tumour, and therefore, why do we observe such a variety of malignant tumours?If for a moment we may assume that the asbestos fibres might produce a bronchogenic carcinoma in asbestos employees with significant exposure, then only two cases (bronchial carcinoma) of the series would serve as evidence because the cases of mesothelioma or lymphosarcoma and cases without exposure or without asbestosis do not have the conditions required".CARTIER [3] listed two workers as having died of pleural mesothelioma, one having worked for 28 yrs in the industry and having had no exposure to asbestos and no asbestosis, and the other having worked for 26 yrs in industry, including 10 yrs of exposure to asbestos, and with minimal asbestosis.The authors refer to a paper by WEDLER [4] as describing two cases of pleural mesothelioma in 1943: apart from these two from his personal experience, he also provided accounts of other unpublished cases of mesothelioma in asbestos workers communicated to him, dating back to 1938.By 1943, German physicians were convinced that asbestos dust exposure was a cause of
Phase <scp>II</scp> multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage <scp>IB</scp> – <scp>IVA</scp> mycosis fungoides/Sézary syndrome
Authors: F. Child, P.L. Ortiz‐Romero, R. Alvarez, M. Bagot, R. Stadler, M. Weichenthal, R. Alves, P. Quaglino, M. Beylot‐Barry, R. Cowan, L.J. Geskin, A. Pérez‐Ferriols, P. Hellemans, Y. Elsayed, C. Phelps, A. Forslund, M. Kamida, P.L. Zinzani
Journal: British Journal of Dermatology (2016)

Quisinostat is a hydroxamate, second‐generation, orally available pan‐histone deacetylase inhibitor. To evaluate the efficacy and safety of oral quisinostat in patients with previously treated cutaneous T‐cell lymphoma (CTCL). Patients received quisinostat 8 mg or 12 mg on days 1, 3 and 5 of each week in 21‐day treatment cycles. Primary efficacy end point was cutaneous response rate (RR) based on the modified Severity Weighted Assessment Tool (mSWAT). Secondary end points included global RR, duration of response (DOR) in skin, progression‐free survival (PFS), pruritus relief, safety and pharmacodynamic markers. Eight of 26 (25 evaluable) patients achieved ≥ 50% reduction in mSWAT score at least once, with confirmed cutaneous response in six (RR 24%). There was a low global RR of 8%. DOR in skin ranged from 2·8 to 6·9 months. Median PFS was 5·1 months. Pruritus relief was more frequent in cutaneous responders (67%) than nonresponders (32%). Serial tumour biopsies revealed an increase in acetylated tubulin, indicating a target effect of histone deacetylase 6. Twenty‐one of 26 (81%) patients were withdrawn from the study before or at clinical cut‐off; five (19%) continued to receive treatment with quisinostat. The most common drug‐related adverse events were nausea, diarrhoea, asthenia, hypertension, thrombocytopenia and vomiting. Grade 3 drug‐related adverse events included hypertension, lethargy, pruritus, chills, hyperkalaemia and pyrexia. Quisinostat 12 mg three times weekly is active in the treatment of patients with relapsed or refractory CTCL, with an acceptable safety profile. Combination therapy with other drugs active in CTCL may be appropriate.
The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease
Authors: Richard L. Sidman, Jianxue Li, Matthew Lawrence, Wenzheng Hu, Gary F. Musso, Ricardo J. Giordano, Marina Cardó-Vila, Renata Pasqualini, Wadih Arap
Journal: Science Translational Medicine (2015)

Blood vessel growth from preexisting vessels (angiogenesis) underlies many severe diseases including major blinding retinal diseases such as retinopathy of prematurity (ROP) and aged macular degeneration (AMD). This observation has driven development of antibody inhibitors that block a central factor in AMD, vascular endothelial growth factor (VEGF), from binding to its receptors VEGFR-1 and mainly VEGFR-2. However, some patients are insensitive to current anti-VEGF drugs or develop resistance, and the required repeated intravitreal injection of these large molecules is costly and clinically problematic. We have evaluated a small cyclic retro-inverted peptidomimetic, D(Cys-Leu-Pro-Arg-Cys) [D(CLPRC)], and hereafter named Vasotide, that inhibits retinal angiogenesis by binding selectively to the VEGF receptors VEGFR-1 and neuropilin-1 (NRP-1). Delivery of Vasotide via either eye drops or intraperitoneal injection in a laser-induced monkey model of human wet AMD, a mouse genetic knockout model of the AMD subtype called retinal angiomatous proliferation (RAP), and a mouse oxygen-induced model of ROP decreased retinal angiogenesis in all three animal models. This prototype drug candidate is a promising new dual receptor inhibitor of the VEGF ligand with potential for translation into safer, less-invasive applications to combat pathological angiogenesis in retinal disorders.
KL-6 compared to LDH as a prognostic factor in Caucasian patients with idiopathic pulmonary fibrosis
Authors: Shinichiro Ohshimo, Francesco Bonella, Yasushi Horimasu, Nobuhisa Ishikawa, Noboru Hattori, Nobuyuki Hirohashi, Koichi Tanigawa, Nobuoki Kohno, Josune Guzman, Ulrich Costabel
Journal: European Respiratory Journal (2012)

BACKGROUNDS:  Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with a poor prognosis. Little is known about sensitive prognostic markers for IPF.   AIMS:  The aim of our study was to investigate the significance of KL-6 compared to LDH as a prognostic marker in Caucasian patients with IPF.   METHODS:  We prospectively collected 79 Caucasian patients with IPF. Serum samples were obtained at enrollment. Serum levels of KL-6 and lactate dehydrogenase (LDH) were measured by ELISA and the correlation between baseline serum levels of the markers and the survival was evaluated.   RESULTS:  Median follow-up period was 372 (1-7088) days. Sixteen (20%) patients died during follow-up. There was no significant difference in the baseline serum KL-6 levels between patients who survived and not survived. Receiver operating characteristic (ROC) curve analysis for predicting non-survival showed larger area under the curve for KL-6 than LDH (0.617 and 0.553, respectively). When the cut-off levels of 1300 U/mL for KL-6 and 280 IU/L for LDH were set, sensitivity, specificity and accuracy for predicting non-survival were 81%, 60% and 66% for KL-6 and 56%, 51% and 52% for LDH. In Kaplan-Meier analysis, patients with baseline serum KL-6 level ≥1300 U/mL showed shorter survival compared with patients with baseline serum KL-6 level    CONCLUSIONS:  Baseline serum KL-6 level ≥1300 U/mL is an independent predictive factor for poor prognosis in Caucasian patients with IPF.
Value of Personalized Medicine
Authors: Ralph Snyderman, Caroline Meade, Connor Drake
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cutaneous lymphomas other than mycosis fungoides: follow-up study of 52 patients.
Authors: P Joly, F Charlotte, M Leibowitch, C Haioun, J Wechsler, F Dreyfus, J P Escande, J Revuz, F Reyes, B Varet
Journal: Journal of Clinical Oncology (1991)

Cutaneous lymphomas other than mycosis fungoides (MF) represent a rare and heterogeneous group of lymphomas. Their clinical behavior remains largely unknown. In this study, the clinical and immunohistologic characteristics and follow-up data of 52 well-documented cases of cutaneous lymphomas other than MF, presenting with initial cutaneous lesions, were reviewed. Twenty-seven patients presented with skin disease alone (stage IE), and 25 patients had concurrent cutaneous and extracutaneous disease (stage IV). The tumors were grouped into high-grade lymphomas (HGLs; 21%), intermediate-grade lymphomas (IGLs; 58%), and low-grade lymphomas (LGLs; 21%). A B-cell phenotype was most often expressed by cutaneous lymphomas (73%), particularly by stage IE lymphomas (85%). Among 13 cases of T-cell lymphomas, loss of one of the pan-T-cell antigens was detected in all cases but one. The clinical course of cutaneous lymphoma was closely dependent on stage and histologic subtype but not on T-cell or B-cell phenotype. Of 20 patients with stage IV HGL or IGL, 13 were treated by polychemotherapy with curative potential. Their median survival was 37 months. Fourteen patients with stage IE HGL or IGL were treated by radiotherapy alone. Nine patients (69%) relapsed within 2 years posttreatment. Seven of them relapsed in the skin outside the initial site involved, suggesting that radiotherapy alone is not an adequate treatment for these patients. Preliminary results concerning seven other patients with stage IE IGL or HGL treated by an initial third-generation polychemotherapy regimen are presented.
Plasminogen-Activating Activity: Association With Steroid Binding by Cytosols of Human Breast Cancers<xref ref-type="fn" rid="FN1">2</xref>
Authors: D J Sutherland
Journal: JNCI Journal of the National Cancer Institute (1980)

Plasminogen-activating activity (PAA) was determined on cytosols prepared from human breast cancers. Coincident assays of steroid-binding proteins were obtained for 119 patients. Significant positive correlations were found between PAA and binding of: 1) estrogen (P less than 0.01), 2) progestin (P less than 0.001), and 3) triamcinolone (P = 0.01). Stepwise regression analysis indicated that variations in the levels of progestin binding accounted for 17% (P less than 0.01) and variations in the levels of triamcinolone binding for 3% (P = 0.05) of the variation observed in PAA. Use of the median value of each assay to discriminate positive from negative values accentuated the positive correlation between PAA and binding of 1) estrogen (P = 3.9 X 10(-5), 2) progestin (P = 1.9 X 10(-4), and 3) triamcinolone (P = 6.1 X 10(-5). Preliminary results suggested that values of PAA equal to or greater than the median correlated positively with response to treatment by hormone manipulation (P = 0.0549). Possible significance of these observations was discussed.
血管閉鎖器具(アンギオシールSTS Plus)の有効性と合併症:807のインターベンションからの経験
Authors: Imai Yoshihiro, Hirohata Atsushi, Hirose Eiki, Seno Keitarou, Nosaka Kazumasa, Ohkawa Keisuke, Yoshida Junji, Ohhara Minako, Satoh Shinji, Toyama Yuko, Shimizu Akinori, Kita Toshimasa, Yamamoto Keizo, Ohe Tohru
Journal: Circulation (2010)
Abstract 19125: Athletes With Repolarization Abnormalities During Exercise Stress Test Have a Lower Global Longitudinal Strain Compared to Hypertensive Patients With the Same Degree of Septal Thickness
Authors: Emilia D’Elia, Paolo Ferrero, Alice Calabrese, Claudia Vittori, Gabriele Cavallaro, Roberta Rossini, Michele Senni
Journal: Circulation (2014)

Introduction: Athletes may have electrocardiographic (ECG) repolarization abnormalities during stress test suggestive for ischemia in the absence of ischemic coronary artery disease. These alterations can be related to a certain degree of septal hypertrophy often associated to intensive training. Global longitudinal strain (GLS) by speckle tracking is a novel technique able to detect segmental alterations in myocardial contractility even in presence of a preserved ventricular function. Hypothesis: GLS might be altered in athletes with ECG repolarization abnormalities at the stress test compared to hypertensive patients with the same degree of septal hypertrophy. Methods: 735 consecutive subjects (mean age 53±12.5 yrs) were enrolled. At the screening stress test, 23 (19 M, 4 F) were found to have ECG repolarization abnormalities suggestive for ischemia in the presence of normal coronary vessels at the multi-slice computed tomography. They were compared to a control group of 10 hypertensive patients (9 M, 1...
GW26-e1532 Targeted Next-Generation Sequencing on Sporadic Thoracic Aortic Aneurysm and Dissection Individuals: Discover the Genetic Connections
Authors: Xuan Zheng, Yi Wu, Ling Li, Jia Du, Jie Zhang, Liang Tao, Zhenlu Zhang
Journal: Journal of the American College of Cardiology (2015)
A phase II trial of oral panobinostat (LBH589), a novel deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis.
Authors: D. J. DeAngelo, A. Tefferi, R. A. Mesa, C. S. Paley, M. Wadleigh, D. Snyder, M. S. Ondovik, J. Rine, K. N. Bhalla
Journal: Journal of Clinical Oncology (2010)

TPS283 Background: Medical treatment options for myelofibrosis (MF) are palliative in nature. Short of allogeneic stem cell transplantation, no therapies are available that are curative or confer a survival benefit. Panobinostat (PAN; LBH589) is a potent pan-deacetylase inhibitor that belongs to a structurally novel cinnamic hydroxamic acid class of compounds. Preclinical studies demonstrated that treatment with PAN alone depletes the levels of JAK2V617F (JAK2) and signaling downstream through STAT3 and 5, AKT, and c-RAF/MAPK in human MPN progenitor cells, including those from patients (pts) with MF (Blood 2009;114:5024). In a prior phase IA/II study of PAN in pts with advanced hematologic malignancies, among 12 pts with MF evaluable for response, 4 pts demonstrated durable clinical improvement. We present a phase II, multicenter, open-label, 2-stage study to further evaluate the efficacy of PAN as a single agent in pts with MF. Methods: Adult pts with PMF, post ET/PV MF who have an IPSS- MF score of 2 or 3 along with either symptomatic splenomegaly (>10 cm below the costal margin [BCM]) or anemia, are eligible. Pts will receive PAN orally 40 mg TIW until disease progression or unacceptable toxicity. There will be 2 cohorts of 20 pts (20 JAK2 mutated, 20 JAK2 wild-type). The study is a 2- stage trial for each independently powered cohort. If no responses are seen in the first 13 pts of either cohort within 6 cycles of treatment, the cohort will be closed to further accrual. Primary endpoint is overall response (CR, PR, and clinical improvement). Secondary endpoints include comparison of responses in pts who are JAK2 mutated to those who are JAK2 wild-type; the symptomatic improvement of MF pts using the Myelofibrosis Symptom Assessment Form, and safety and tolerability of PAN in MF pts. Exploratory endpoints include correlative biomarker studies. As of January 12, 2010, 8 pts have been enrolled. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis Novartis Novartis Novartis
&lt;italic&gt;Herpesvirus saimiri:&lt;/italic&gt; VII. Induction of Malignant Lymphoma in New Zealand White Rabbits&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: M D Daniel, L V Meléndez, R D Hunt, N W King, M Anver, C E Fraser, H Barahona, R B Baggs
Journal: JNCI Journal of the National Cancer Institute (1974)

Herpesvirus saimiri and squirrel monkey heart isolate, a closely related strain of H. saimiri, induced malignant lymphomas in New Zealand White rabbits in as few as 17 days by a single intravenous inoculation. The duration of the disease in rabbits varied from 17 to 149 days. Both light and electron microscopy revealed a close resemblance between these rabbit lymphomas and H. saimiri-induced lymphomas in monkeys.